AAIC 2025 Abstract
The VIVA‐MIND study: Topline Results from Phase 2 RCT of Varoglutamstat in Early AD
Trial in peopleInterventions
Abstract
Background: Varoglutamstat (PQ912) is an oral small molecule inhibitor of glutaminyl cyclases which reduces the pyroglutamate formation of Aβ and CCL2. Preclinical and Ph1 trials support this Ph2 evaluation in early AD.
